Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sanofi and Regeneron's Dupixent succeeds in trial of chronic hives
Sanofi and Regeneron's Dupixent showed significant improvement in chronic spontaneous urticaria patients in a Phase 3 trial, with 30% achieving complete response versus 18% on placebo, moving closer to FDA approval.
Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD studies
Dupixent reduced COPD exacerbations and improved lung function in adults with type 2 inflammation, according to BOREAS and NOTUS phase 3 studies. Dupixent was approved by the European Medicines Agency as an add-on treatment for uncontrolled COPD patients on maximal inhaled therapy. The pooled analysis showed a 31% reduction in exacerbations and a 147 mL improvement in lung function compared to placebo, with safety consistent with known profiles.
Dupixent Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria
Dupixent Phase 3 trial (LIBERTY-CUPID Study C) met primary and key secondary endpoints for treating uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) with antihistamines, showing significant reductions in itch and hives. Dupixent-treated patients reported a 50% reduction in itch and urticaria activity scores compared to placebo, with 30% achieving complete response. Safety results were consistent with known profiles, and detailed results will be submitted to the FDA by year-end 2024.
Dupixent is the first and only biologic to achieve significant improvements in ...
Dupixent showed significant improvements in disease remission and symptoms in bullous pemphigoid, meeting primary and secondary endpoints, with five times more patients achieving remission compared to placebo. It's the first medicine to show a significant steroid-sparing effect and could be the first targeted treatment for BP in the U.S. and EU if approved.
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Transgene announces the appointment of Dr. Emmanuelle Dochy as Chief Medical Officer and Dr. Maurizio Ceppi as Chief Scientific Officer to advance cancer immunotherapies and precision medicine. Both appointees bring extensive experience in oncology and clinical development. Dr. Dochy succeeds Dr. Maud Brandely, and Dr. Ceppi succeeds Eric Quéméneur, who are both retiring or pursuing other interests. The new leadership positions Transgene to deliver innovative treatments to cancer patients.
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With ...
Vir Biotechnology closed a strategic agreement with Sanofi, gaining exclusive worldwide licenses to three clinical-stage masked T-cell engagers (TCEs) for cancer treatments and the PRO-XTEN masking platform for oncology and infectious disease. The TCEs include SAR446309 (HER2-targeted), SAR446329 (PSMA-targeted), and SAR446368 (EGFR-targeted), with clinical studies underway or planned. Key Sanofi employees with expertise in TCEs and the PRO-XTEN platform will join Vir.
Paris court revokes Sanofi cabazitaxel patent
The Judicial Court of Paris revoked Sanofi’s EP 2 493 466 patent on cabazitaxel due to obviousness, marking another setback in the dispute with generic drug companies over Jevtana. French judges consistently favor generics in pharmaceutical disputes. Sanofi’s second medical use patent for cabazitaxel, used in Jevtana, faces ongoing challenges from Teva, Accord Healthcare, and Ever Pharma. The EPO Technical Boards of Appeal will hear an appeal against the patent’s grant in April 2025, and UPC cases are pending.
Vir Biotechnology names new CFO to boost financial strategy
Vir Biotechnology Inc. appoints Jason O'Byrne as EVP and CFO, effective October 2, 2024. O'Byrne brings over two decades of financial and operational experience, including roles at Caribou Biosciences and Audentes Therapeutics. Vir focuses on infectious diseases and cancer treatments, with recent FDA approvals and a licensing deal with Sanofi. The company is restructuring, reducing workforce by 25%, and faces financial challenges despite holding more cash than debt.
New report investigates pharma's global reach and impact
A report by the Access to Medicine Foundation examines how 20 major pharmaceutical companies are addressing patient access in low- and middle-income countries (LMICs), highlighting progress and areas needing improvement. The report identifies 42 different approaches to measuring patient reach, with 19 companies actively tracking this, but no industry-wide consensus. It calls for clearer, more actionable commitments to ensure lifesaving products reach underserved populations, emphasizing the need for collaboration and refining measurement methods to address health inequities.
© Copyright 2025. All Rights Reserved by MedPath